IGC Pharma, Inc. (IGC)

NYSE: IGC · Pharmaceutical Preparations · Potomac, MD · filing with the SEC since 2005

Full chart Alerts Compare

Grade5.0

◀ Past 4.0● Present 6.2▶ Future 4.7

3 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The grade of IGC Pharma, Inc.

Nine metrics read from its own filings, by tense

Headline grade

5.0/10

◀ Past4.025% of the headline

● Present6.235% of the headline

▶ Future4.740% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 6 read as filed from the record and 3 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

4.0/1025% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed

4.1/10

Has it survived what it has been through?

16 warning events since 2017; the latest 2023-06-30.

weight 22% of this tense · 41st percentile among 497 sector filers · read for itself

From the record

IGC Pharma, Inc.'s filings since 2017 show 16 warning events of 3 kinds: a notice about its exchange listing (8-K item 3.01, 5 times, the latest 2018-11-13); an auditor change (8-K item 4.01, 2 times, the latest 2018-04-12); a late-report notice (Form NT 10-K or NT 10-Q, 9 times, the latest 2023-06-30) (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed

2.6/10

What has it actually done, year after year?

-16.4% a year over 10 filed years; profitable in 0 of 10.

weight 45% of this tense · 26th percentile among 323 sector filers · read for its customers

From the record

IGC Pharma, Inc.'s 10 filed years say what it did: revenue went from $6 million in fiscal 2016 to $1 million in fiscal 2025, down 16.4% a year; it rose in 4 of 9 years; the deepest fall was 94% from fiscal 2016 to fiscal 2022; net income was positive in 0 of 10 of those years (its annual reports).

What it rests on

revenue growth over the filed span-16.4%bottom 17% of its family
the share of years revenue rosebottom 29% of its family
the share of filed years with a profitbottom 27% of its family
the deepest fall from a revenue peak93.8%bottom 31% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate

5.8/10

How has it treated the people who own it?

SI estimate 5.8/10, confidence 20 of 100 (family median).

weight 33% of this tense · 50th percentile among 295 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income, so the desk assumes the typical reading of its industry family, the median of 295 members with one.
What the record cannot read: Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned: family median, 295 readings behind it.
Confidence: 20 of 100
What would change it: Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: IGC Pharma, Inc.'s shareholder treatment is put at 5.8 of 10 with a confidence of 20 of 100, because fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income, so the desk assumes the typical reading of its industry family, the median of 295 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

● Present

What are they doing right now?

6.2/1035% of the headline grade · 2 of 3 filed, 1 estimated

Financial health

SI estimate

5.1/10

Is it financially healthy right now?

SI estimate 5.1/10, confidence 20 of 100 (family median).

weight 45% of this tense · 50th percentile among 480 sector filers · read for itself

SI estimate Inferred, not read as filed

Why it is an estimate: Fewer than two of the four checks can be read, so the desk assumes the typical reading of its industry family, the median of 480 members with one.
What the record cannot read: Fewer than two of the four checks can be read.
How it was reasoned: family median, 480 readings behind it.
Confidence: 20 of 100
What would change it: Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: IGC Pharma, Inc.'s financial health is put at 5.1 of 10 with a confidence of 20 of 100, because fewer than two of the four checks can be read, so the desk assumes the typical reading of its industry family, the median of 480 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

Industry position

as filed

4.6/10

How strong is its position in its industry?

bottom 46% of 315 in its family; net margin -560.3%.

weight 22% of this tense · 46th percentile among 315 sector filers · read for its customers

From the record

IGC Pharma, Inc.'s standing among 315 graded names in its industry family: revenue of $1 million in fiscal 2025 ranks in the bottom 25% by size; a net margin of -560.3% ranks in the bottom 36%; revenue growth of 47.4% a year over the last 3 filed years ranks in the top 24% (its annual reports).

What it rests on

revenue against the family$1.3Mbottom 25% of its family
net margin-560.3%bottom 36% of its family
three-year revenue growth47.4%top 24% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

as filed

8.8/10

What are the people in charge doing?

top 12% of 315 in its family for leadership; chief executive since 2006.

weight 33% of this tense · 88th percentile among 315 sector filers · read for its shareholders

From the record

IGC Pharma, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Mukunda, Ram (CEO, as filed), filing under that title since 2006-03-15, 20.7 years (top 1% of its family); the 5 officers and directors filing in the last fifteen months have been on the record a median of 8.3 years (top 19%); 1 officer or director change was reported on Form 8-K since 2023-11-13, against the 5 people in charge now (top 16%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

What it rests on

officer and director changes on Form 8-K, against the people in charge1 in three years among 5 peopletop 16% of its family
the median years the people in charge have filed8.3 yearstop 19% of its family
the chief executive's years on the record20.7 yearstop 1% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

▶ Future

What are they set up to do next?

4.7/1040% of the headline grade · 2 of 3 filed, 1 estimated

Room to expand

SI estimate

2.2/10

How much room does it have to grow?

SI estimate 2.2/10, confidence 35 of 100 (one part).

weight 33% of this tense · 22nd percentile among 479 sector filers · read for itself

SI estimate Inferred, not read as filed

Why it is an estimate: Read from one part only, cash less debt against assets, which ranks in the bottom 22% of 479 in its family; the record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue.
What the record cannot read: The record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue.
How it was reasoned: one part: cash less debt against assets, the one part on file, ranked among 479 in its family.
Confidence: 35 of 100
What would change it: A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: IGC Pharma, Inc.'s room to expand is put at 2.2 of 10 with a confidence of 35 of 100, because read from one part only, cash less debt against assets, which ranks in the bottom 22% of 479 in its family; the record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue. A filing that carries the missing parts replaces this estimate with the filed reading.

Growth drivers

as filed

5.9/10

What could actually drive growth from here?

top 41% of 306 in its family for growth drivers.

weight 45% of this tense · 59th percentile among 306 sector filers · read for its customers

From the record

IGC Pharma, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 47.4% a year over the last three filed years against -16.4% over all 10, speeding up (top 8% of its family); the newest year grew -5.5% (bottom 31%); research spending grew 16.2% a year (top 28%); capital spending grew -22% a year (bottom 42%) (its annual reports). IGC Pharma, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

three-year growth against the whole span+63.8 points a yeartop 8% of its family
the newest year's revenue growth-5.5%bottom 31% of its family
three-year growth of research spending16.2%top 28% of its family
three-year growth of capital spending-22.0%bottom 42% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

as filed

5.7/10

Did its newest year beat what its own record pointed to?

top 43% of 233 in its family for expectations against reality.

weight 22% of this tense · 57th percentile among 233 sector filers · read for its shareholders

From the record

IGC Pharma, Inc.'s newest year against its own record: revenue of $1 million in fiscal 2025 came in 48.6% below the $2 million its prior three years' pace pointed to (bottom 19% of its family); net income of $7 million against a prior three-year average of $13 million (top 34%); a net margin of a loss larger than its revenue against losses larger than its revenue before (top 14%) (its annual reports).

What it rests on

revenue against the prior three years' pace-48.6%bottom 19% of its family
net income against the prior three years' average+46%top 34% of its family
net margin against its prior averageup more than 100 pointstop 14% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton IGC · research, not advice